Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with ...
Biogen announces initiation of dosing in TRANSCEND
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
GlobalData on MSN2d
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR
In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.
Unleased lab space. Plunging valuations. Layoffs. In Massachusetts, the biotech slump is taking its toll.
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.
Pharmabiz1d
Biogen begins TRANSCEND phase 3 study of felzartamab to treat late antibody-mediated rejection in kidney transplant patients
Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...
Morningstar3d
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
“Building upon the promising results from the ... its clinical development,” said Travis Murdoch, Head of HI-Bio at Biogen. “Losing a kidney after receiving a long-awaited transplant is ...
Nasdaq3d
Biogen Initiates Phase 3 TRANSCEND Study to Evaluate Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
“Building upon the promising results from the ... its clinical development,” said Travis Murdoch, Head of HI-Bio at Biogen Losing a kidney after receiving a long-awaited transplant is ...
STAT1d
In the Boston area, biotech’s hub, a slump is being acutely felt
In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.